Natco announces launch of the first generic version of Revlimid in the US market; Stock soars 3.5%

8 Mar 2022 , 11:16 AM

Natco Pharma Limited launched its first generic version of Revlimid (Lenalidomide capsules), in the US market along with its marketing partner Arrow International Ltd (an affiliate of Teva Pharmaceutical Industries Ltd).

These capsules are available in 5mg, 1Omg, 15mg, and 25mg strengths. The drug is used for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment.

Natco and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).

At around 11.20 am, Natco Pharma Ltd was trading at Rs874.15 per piece up by Rs29.85 or 3.54% from its previous closing of Rs844.30 per piece on the BSE. The scrip opened at Rs880 and has touched a high and low of Rs920 and Rs852.05 respectively.